Skip to main content
SpringerLink
Log in

Introduction, Diagnostic Criteria, Pharmacotherapy, and Dental Management

  • Chapter
  • First Online:
Sjögren's Syndrome and Oral Health

  • 541 Accesses

Abstract

The focus of this chapter is to present the basic clinical signs and symptoms, diagnostic strategies, and management approaches of SS for the oral health team. As the disease spectrum for SS is wide and quite variable, diagnosis can be challenging. This chapter will present evidence-based diagnostic and management strategies in a sequential fashion. More specifically, these include published diagnostic criteria, signs and symptoms, selected chairside patient questions suggestive of SS, and distinctions between xerostomia and hyposalivation. Chairside procedures to measure salivary flow rates and perform labial salivary gland biopsies are presented as well. Essential serological screening tests for diagnosis of SS and the subsequent need for interprofessional involvement are reviewed. Pharmacologic and non-pharmacologic treatments provided by the oral health care team for SS are detailed. These include products to relieve dry mouth, caries prevention agents, and medications to manage the oral manifestations SS. The dental management section includes patient counseling, caries management, discussion of TMD symptoms, association of SS and periodontal disease, and implant therapy. A positive and supportive approach to managing SS patients will empower them to take an active role in their oral health and improve their quality of life. Any patient presenting with xerostomia should receive a thorough evaluation. Of significance, the dentist and/or dental hygienist may be the first health care professional to suspect and facilitate the diagnosis of SS. This chapter will sequentially present the key elements in the management of patients with xerostomia, hyposalivation, and rheumatic diseases such as SS. This clinical-based approach will serve as a valuable reference for the oral health team as well as the interprofessional medical team consisting of (at a minimum) rheumatologists, ophthalmologists, and primary care physicians.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Patel R, Shahane A. The epidemiology of Sjögren’s syndrome. Clin Epidemiol. 2014;6:247–55. https://doi.org/10.2147/CLEP.S47399.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR. Estimating the prevalence among Caucasian women of primary Sjogren’s syndrome in two general practices in Birmingham, UK. Scand J Rheumatol. 2004;33:39–43.

    Article  PubMed  Google Scholar 

  3. Westhoff G, Zink AZ. Epidemiology of primary Sjogren’s syndrome. Z Rheumatol. 2010;69:41. https://doi.org/10.1007/s00393-009-0518-3.

    Article  PubMed  Google Scholar 

  4. Stewart CM, Berg KM, Cha S, Reeves WH. Salivary dysfunction and quality of life in Sjögren’s syndrome—a critical oral-systemic connection. JADA. 2008;139(3):219–99.

    Google Scholar 

  5. Fox RI. Sjögren’s syndrome. Lancet. 2005;366:321–31.

    Article  PubMed  Google Scholar 

  6. Bayetto K, Logan RM. Sjögren’s syndrome: a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J. 2010;55(Suppl 1):39–47.

    Article  PubMed  Google Scholar 

  7. Ienopoli S, Carsons SE. Extraglandular manifestations of primary Sjögren’s syndrome. Oral Maxillofac Surg Clin North Am. 2014;26:91–9.

    Article  PubMed  Google Scholar 

  8. Sjogren’s Syndrome Foundation. 2019. https://www.sjogrens.org/home/about-sjogrens.

  9. Solans-Laque R, Lopez-Herandez A, Bosch-Gill JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren’s syndrome. Semin Arthritis Rheum. 2011;41(3):415–23.

    Article  PubMed  Google Scholar 

  10. Johnsen SJ, Brun JG, Gøransson LG, Småstuen MC, Johannesen TB, Haldorsen K, et al. Risk of non-Hodgkin’s lymphoma in primary Sjögren’s syndrome: a population-based study. Arthritis Care Res (Hoboken). 2013;65(5):816–21.

    Article  Google Scholar 

  11. Brito-Zeron P, Theander E, Baldini C, Seror R, Retamozo S, Quartuccio L, et al. Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol. 2016;12:137–56.

    Article  PubMed  Google Scholar 

  12. Pinto A. Management of xerostomia and other complications of Sjögren’s syndrome. Oral Maxillofac Surg Clin North Am. 2014;26(1):63–73.

    Article  PubMed  Google Scholar 

  13. Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc. 1987;115:581–4.

    Article  PubMed  Google Scholar 

  14. Manthorpe R, Oxholm P, Prause JU, Schiødt M. The Copenhagen criteria for Sjögren’s syndrome. Scand J Rheumatol Suppl. 1986;61:19–21.

    PubMed  Google Scholar 

  15. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis. 2002;61:554–8.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475–87.

    Article  Google Scholar 

  17. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. International Sjögren’s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16. https://doi.org/10.1136/annrheumdis-2016-210571.

    Article  PubMed  Google Scholar 

  18. Atkinson JC, Fox PC. Sjogren’s syndrome: oral and dental considerations. J Am Dental Assoc. 1993;124(3):74–6, 78-82, 84-6.

    Article  Google Scholar 

  19. Fox PC, Bowman SJ, Segal B, Vivino FB, Murukutla N, Choueiri K, et al. Oral involvement in primary Sjögren syndrome. J Am Dent Assoc. 2008;139:1592–601.

    Article  PubMed  Google Scholar 

  20. Hopcraft MS, Tan C. Xerostomia: an update for clinicians. Aust Dent J. 2010;55(3):238–44.

    Article  PubMed  Google Scholar 

  21. Fox PC, van der Ven PF, Sonies BC, Weiffenbach JM, Baum BJ. Xerostomia: evaluation of a symptom with increasing significance. J Am Dent Assoc. 1985;110(4):519–25.

    Article  PubMed  Google Scholar 

  22. Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent. 2001;85(2):162–9.

    Article  PubMed  Google Scholar 

  23. Pedersen AM, Bardow A, Jensen SB, Nauntofte B. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis. 2002;8:117–29.

    Article  PubMed  Google Scholar 

  24. Screebny LM, Valdini A. Xerostomia. A neglected symptom. Arch Intern Med. 1987;147:1333–7.

    Article  Google Scholar 

  25. Heintze U, Birkhed D, Björn H. Secretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sex. Swed Dent J. 1983;7:227–38.

    PubMed  Google Scholar 

  26. Daniels TE, Silverman S Jr, Michalski JP, Greenspan JS, Sylvester RA, Talal N. The oral component of Sjogren’s syndrome. Oral Surg Oral Med Oral Pathol. 1975;39:875–85.

    Article  PubMed  Google Scholar 

  27. Tapper-Jones L, Aldred M, Walker DM. Prevalence and intraoral distribution of Candida albicans in Sjogren’s syndrome. J Clin Pathol. 1980;33:282–7.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Radfar L, Shea Y, Steven FH, Sankar V, Leakan RA, Baum B, et al. Fungal load and candidiasis in Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96:283–7.

    Article  PubMed  Google Scholar 

  29. Yan Z, Young AL, Hua H, Xu Y. Multiple oral Candida infections in patients with Sjögren syndrome—prevalence and clinical and drug susceptibility profiles. J Rheumatol. 2011;38:2428–31.

    Article  PubMed  Google Scholar 

  30. Mathews SA, Kurien BT, Scofield RH. Oral manifestations of Sjögren’s syndrome. J Dent Res. 2008;87(4):308–18.

    Article  PubMed  Google Scholar 

  31. Navazesh M, Kumar SK. Measuring salivary flow: challenges and opportunities. JADA. 2008;139(5 suppl):35S–40S.

    PubMed  Google Scholar 

  32. Inoue H, Ono K, Masuda W, Morimoto Y, Tanaka T, Yokota M, et al. Gender difference in unstimulated whole saliva flow rate and salivary gland sizes. Arch Oral Biol. 2006;51(12):1055–60. https://doi.org/10.1016/j.archoralbio.2006.06.010.

    Article  PubMed  Google Scholar 

  33. López-Jornet P, Camacho-Alonso F, Bermejo-Fenoll A. A simple test for salivary gland hypofunction using Oral Schirmer’s test. J Oral Pathol Med. 2006;35:193–256. https://doi.org/10.1111/j.1600-0714.2006.00411.x.

    Article  Google Scholar 

  34. Fontana M, Zunt S, Eckert GJ, Zero D. A screening test for unstimulated salivary flow measurement. Oper Dent. 2005;30(1):3–8.

    PubMed  Google Scholar 

  35. Nardi N, Brito-Zeron P, Ramos-Casals M, Aguiló S, Cervera R, Ingelmo M, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol. 2006;25(3):341–6.

    Article  PubMed  Google Scholar 

  36. Pisetsky DS. Antinuclear antibodies in healthy people: the tip of autoimmunity’s iceberg? Arthritis Res Ther. 2011;13(2):109. https://doi.org/10.1186/ar3282.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Daniels TE, Cox D, Shiboski CH, Schiødt M, Wu A, Lanfranchi H, et al. Sjögren’s International Collaborative Clinical Alliance Research Groups. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren’s syndrome among 1,726 registry participants. Arthritis Rheum. 2011;63(7):2021–30. https://doi.org/10.1002/art.30381.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. Nat Rev Rheumatol. 2016;12:456–71.

    Article  PubMed  Google Scholar 

  39. Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Medicine (Baltimore). 2016;95(25):e3766. https://doi.org/10.1097/MD.0000000000003766.

    Article  Google Scholar 

  40. Karagozoglu KH, De Visscher JG, Forouzanfar T, van der Meif EH, Jager DJ. Complications of Sialendoscopy in patients with Sjögren syndrome. J Oral Maxillofac Surg. 2017;75(5):978–83. https://doi.org/10.1016/j.joms.2016.09.046.

    Article  PubMed  Google Scholar 

  41. Nahlieli O, Baruchin AM. Long-term experience with endoscopic diagnosis and treatment of salivary gland inflammatory diseases. Laryngoscope. 2000;110(6):988–93. https://doi.org/10.1097/00005537-200006000-00020.

    Article  PubMed  Google Scholar 

  42. Rasmussen ER, Lykke E, Wagner N, Nielsen T, Waersted S, Arndal H. The introduction of sialendoscopy has significantly contributed to a decreased number of excised salivary glands in Denmark. Eur Arch Otorhinolaryngol. 2016;273(8):2223–30. https://doi.org/10.1007/s00405-015-3755-x.

    Article  PubMed  Google Scholar 

  43. Strychowsky JE, Sommer DD, Gupta MK, Cohen N, Nahlieli O. Sialendoscopy for the management of obstructive salivary gland disease: a systematic review and meta-analysis. Arch Otolaryngol Head Neck Surg. 2012;138:541–7.

    Article  PubMed  Google Scholar 

  44. Karagozoglu KH, Vissink A, Forouzanfar T, Brand HS, Maarse F, Jager DJ. Sialendoscopy enhances salivary gland function in Sjögren’s syndrome: a 6-month follow-up, randomised and controlled, single blind study. Ann Rheum Dis. 2018;77(7):1025–31. Epub 2018 Feb 23. https://doi.org/10.1136/annrheumdis-2017-212672.

    Article  PubMed  Google Scholar 

  45. Villa A, Connell CL, Abati S. Diagnosis and management of xerostomia and hyposalivation. Ther Clin Risk Manag. 2014;11:45–51.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Peldyak J, Makinen KK. Xylitol for caries prevention. J Dent Hyg. 2002;76(4):276–85.

    PubMed  Google Scholar 

  47. Zero DT, Brennan MT, Daniels TE, Papas A, Stewart C, Pinto A, et al. Clinical practice guidelines for oral management of Sjögren disease: dental caries prevention. JADA. 2016;147(4):295–305.

    PubMed  Google Scholar 

  48. Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs. 1995;49(1):143–55.

    Article  PubMed  Google Scholar 

  49. Papas AS, Fernandez MM, Castano RA, Gallagher SC, Trivedi M, Shrotriya RC. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögren’s syndrome. Adv Exp Med Biol. 1998;438:973–8.

    Article  PubMed  Google Scholar 

  50. Rhodus NL, Schuh MJ. Effects of pilocarpine on salivary flow in patients with Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol. 1991;72(5):545–9.

    Article  PubMed  Google Scholar 

  51. Salagen (pilocarpine hydrochloride) [FDA prescribing information]. Woodcliffe Lake, NJ: Eisai; 2018.

    Google Scholar 

  52. Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren’s syndrome: a randomized trial. Arch Intern Med. 2002;162(11):1293–300.

    Article  PubMed  Google Scholar 

  53. Fox RI. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren’s syndrome. Adv Exp Med Biol. 2002;506(Pt B):1107–16.

    Article  PubMed  Google Scholar 

  54. Noaiseh G, Baker JF, Vivino FB. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren syndrome. Clin Exp Rheumatol. 2014;32:575–7.

    PubMed  Google Scholar 

  55. Brimhall J, Jhaveri MA, Yepes JF. Efficacy of cevimeline vs pilocarpine in secretion of saliva: a pilot study. Spec Care Dentist. 2013;33:123–7.

    Article  PubMed  Google Scholar 

  56. Strietzel FP, Martın-Granizo R, Fedele S, Lo Russo L, Mignogna M, PA Reichart PA, Wolff A. Electrostimulating device in the management of xerostomia. Oral Dis. 2007;13:206–13. https://doi.org/10.1111/j.1601-0825.2006.01268.x.

    Article  PubMed  Google Scholar 

  57. Sivaramakrishnan G, Sridharan K. Electrical nerve stimulation for xerostomia: a meta-analysis of randomised controlled trials. J Tradit Complement Med. 2017;7(4):409–13. Published online 2017 Feb 14. https://doi.org/10.1016/j.jtcme.2017.01.004.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Villa A, Wolff A, Narayana N, Dawes C, Aframian DJ, Lynge AM, et al. World workshop on Oral medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis. 2016;22:365–82. https://doi.org/10.1111/odi.12402.

    Article  PubMed  Google Scholar 

  59. Singh ML, Papas A. Oral implications of polypharmacy in the elderly. Dent Clin N Am. 2014;58(4):783–96.

    Article  PubMed  Google Scholar 

  60. Food and Drug Administration Consumer Alerts. https://www.fda.gov/consumers/consumer-updates/paws-xylitol-its-dangerous-dogs

  61. Visvanathan V, Nix P. Managing the patient presenting with xerostomia: a review. Int J Clin Pract. 2010;64(3):404–7.

    Article  PubMed  Google Scholar 

  62. Olsson P, Turesson C, Mandl T, Jacobsson L, Theander E. Cigarette smoking and the risk of primary Sjögren’s syndrome: a nested case control study. Arthritis Res Ther. 2017;19(1):50. https://doi.org/10.1186/s13075-017-1255-7.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Gorin SS, Heck JE. Meta-analysis of the efficacy of tobacco counseling by health care providers. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2012–22.

    PubMed  Google Scholar 

  64. Zunt SL. Xerostomia/salivary gland hypofunction: diagnosis and management. Compend Contin Educ Dent. 2018;9(6):365–9.

    Google Scholar 

  65. Soto-Rojas AE, Villa AR, Sifuentes-Osornio J, Alarcón-Segovia D, Kraus A. Oral candidiasis and Sjögren’s syndrome. J Rheumatol. 1998;25(5):911–5.

    PubMed  Google Scholar 

  66. Najera MP, Al-Hashimi I, Plemons JM, Rivera-Hidalgo F, Rees TD, Haghighat N, Wright JM. Prevalence of periodontal disease in patients with Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83:453–7.

    Article  PubMed  Google Scholar 

  67. Le Gall M, Cornec D, Pers JO, Saraux A, Jousse-Joulin S, Cochener B, et al. A prospective evaluation of dental and periodontal status in patients with suspected Sjögren’s syndrome. Joint Bone Spine. 2016;83(2):235–6.

    Article  PubMed  Google Scholar 

  68. Boutsi EA, Paikos S, Dafni UG, Moutsopoulos HM, Skopouli FN. Dental and periodontal status of Sjögren’s syndrome. J Clin Periodontol. 1999;27:231–5.

    Article  Google Scholar 

  69. Schiødt M, Christensen LB, Petersen PE, Thorn II. Periodontal disease in primary Sjögren’s syndrome. Oral Dis. 2001;7:106–8.

    PubMed  Google Scholar 

  70. Kuru B, McCullough MJ, Yilmaz S, Porter SR. Clinical and microbiological studies of periodontal disease in Sjögren syndrome patients. J Clin Periodontol. 2002;29:92–102.

    Article  PubMed  Google Scholar 

  71. Jorkjend L, Johansson A, Johansson K, Bergenholtz A. Periodontitis, caries and salivary factors in Sjögren’s syndrome patients compared to sex- and age-matched controls. J Oral Rehabil. 2003;30:369–78.

    Article  PubMed  Google Scholar 

  72. Li R, Tian C, Postlethwaite A, Jiao Y, Garcia-Godoy F, Pattanaik D, et al. Rheumatoid arthritis and periodontal disease: what are the similarities and differences? Int J Rheum Dis. 2017;20(12):1887–901.

    Article  PubMed  Google Scholar 

  73. Mankia K, Cheng Z, Do T, Hunt L, Meade J, Kang J, et al. Prevalence of periodontal disease and periodontopathic bacteria in anti-citrullinated protein antibody-positive at risk adults without arthritis. JAMA Netw Open. 2019;2(6):e195394. https://doi.org/10.1001/jamanetworkopen.2019.5394.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Crincoli V, Di Comite M, Guerrieri M, Rotolo RP, Limongelli L, Tempesta A, et al. Orofacial manifestations and temporomandibular disorders of Sjögren syndrome: an observational study. Int J Med Sci. 2018;15(5):475–83.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Zanin MC, Garcia DM, Rocha EM, de Felicio CM. Orofacial motor functions and temporomandibular disorders in patients with Sjogren’s syndrome. Arthritis Care Res (Hoboken). 2019;72:1057–65. [Epub ahead of print]. https://doi.org/10.1002/acr.24001.

    Article  Google Scholar 

  76. Young DA, Frostad-Thomas A, Gold J, Wong A. Secondary Sjögren syndrome; a case report using silver diamine fluoride and glass ionomer cement. J Am Dent Assoc. 2018;149(8):731–41. https://doi.org/10.1016/j.adaj.2018.03.021.

    Article  PubMed  Google Scholar 

  77. Chrcanovic BR, Kisch J, Wennerberg A. Dental implants in patients with Sjögren’s syndrome: a case series and a systematic review. Int J Oral Maxillofac Surg. 2019;48(9):1250–9. Feb 28. pii: S0901–5027(19)30069–4. https://doi.org/10.1016/j.ijom.2019.02.005.

    Article  PubMed  Google Scholar 

  78. Albrecht K, Callhoff J, Westhoff G, Dietrich T, Dörner T, Zink A. The prevalence of dental implants and related factors in patients with Sjögren syndrome: results from a cohort study. J Rheumatol. 2016;43(7):1380–5.

    Article  PubMed  Google Scholar 

  79. Korfage A, Raghoebar GM, Arends S, Meiners PM, Visser A, Kroese FG, et al. Dental implants in patients with Sjögren’s syndrome. Clin Implant Dent Relat Res. 2016;18(5):937–45.

    Article  PubMed  Google Scholar 

  80. Wu AJ. Management of salivary hypofunction in Sjögren’s syndrome. Curr Treat Options Rheumatol. 2015;1(3):255–68.

    Article  Google Scholar 

  81. Ramos-Casals M, Brito-Zeron P, Solans R, Camps MT, Casanovas A, Sopeña B, et al. Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford). 2014;53(2):321–31.

    Article  Google Scholar 

  82. Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sjögren’s syndrome. Eur Respir Rev. 2016;25:110–23.

    Article  PubMed  Google Scholar 

  83. Evans R, Zdebik A, Ciurtin C, Walsh SB. Renal involvement in primary Sjögren’s syndrome. Rheumatology (Oxford). 2015;54(9):1541–8.

    Article  Google Scholar 

  84. Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, et al. Treatment guidelines for rheumatologic manifestations of Sjogren’s: use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken). 2017;69(4):517–27. Epub 2017 Mar 3. Review. https://doi.org/10.1002/acr.22968.

    Article  Google Scholar 

  85. Brito-Zerón P, Retamozo S, Kostov B, Baldini C, Bootsma H, De Vita S, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome. RMD Open. 2019;5(2):e001064. https://doi.org/10.1136/rmdopen-2019-001064.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al. EULAR Sjögren’s Task Force. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382–9. https://doi.org/10.1136/annrheumdis-2014-206008.

    Article  PubMed  Google Scholar 

  87. Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015;1(1):e000022. https://doi.org/10.1136/rmdopen-2014-000022.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, et al. EULAR Sjögren’s Task Force. Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2015;74(5):859–66. https://doi.org/10.1136/annrheumdis-2013-204615.

    Article  PubMed  Google Scholar 

  89. Gandía M, Morales-Espinoza EM, Martín-González RM, Retamozo S, Kostov B, Belenguer-Prieto R, et al. Factors influencing dry mouth in patients with primary Sjögren syndrome: usefulness of the ESSPRI index. Oral Health Dent Manag. 2014;13(2):402–7.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oral and Maxillofacial Diagnostic Sciences, College of Dentistry, University of Florida, Gainesville, FL, USA

    Carol M. Stewart

Authors
  1. Carol M. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol M. Stewart .

Editor information

Editors and Affiliations

  1. Center for Orphaned Autoimmune Disorders, University of Florida, College of Dentistry, Gainesville, FL, USA

    Seunghee Cha

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Stewart, C.M. (2021). Introduction, Diagnostic Criteria, Pharmacotherapy, and Dental Management. In: Cha, S. (eds) Sjögren's Syndrome and Oral Health. Springer, Cham. https://doi.org/10.1007/978-3-030-72029-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-72029-2_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-72028-5

  • Online ISBN: 978-3-030-72029-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation